Irifrin drops Ch. 2.5% 5ml vial

$13.74

Irifrin drops Ch. 2.5% 5ml vial

Quantity:

SKU: 774558138 Categories: , , Tag:

Description

Composition
Active substance:
1 ml of solution contains: 25 mg of phenylephrine hydrochloride ,.
Excipients:
Benzalkonium chloride 0.1 mg Disodium edetate 1.0 mg, 3.0 mg of hypromellose, 2.0 mg of sodium metabisulfite, citric acid 1.16 mg Sodium citrate dihydrate 7.5 mg Water for injection q.s.
Description:
The clear solution from colorless to pale yellow.
Product form:
Eye drops of 2.5% or 10%
– On 5 ml vial dark glass, covered by a rubber stopper, a crimped aluminum cap with plastic safety cap. In one glass vial with a sterile dropper, packed in a plastic bag and placed in a cardboard box, together with instructions for use.
– 5 mL plastic dropper-bottle screw cap.
Each vial-IV together with instructions for use placed in a cardboard box.
Contraindications
Hypersensitivity to the drug.
Or narrow-angle closure glaucoma.
The drug is contraindicated in elderly patients with serious disorders of the cardiovascular or cerebrovascular system.
Contraindicated for use of the drug for an additional extension of the pupil during surgery in patients with impaired integrity of the eyeball, as well as in violation of tear production. 10% solution of the drug is contraindicated in children under 12 years of age and patients with aneurysms. 2.5% solution in premature drug contraindicated.
Hyperthyroidism.
Hepatic porphyria.
Congenital deficiency of glucose-6-phosphate dehydrogenase.
Carefully.
In patients with diabetes – increased blood pressure increase the risk associated with impaired autonomic regulation.
Elderly patients – increased risk of reactive miosis.
The simultaneous use of MAO inhibitors (including for 21 days after termination of the reception)
Exceeding the recommended dose of a 2.5% solution in patients with injuries, eye diseases or its appendages, postoperative or with decreased tear production (anesthesia) can lead to increased absorption of phenylephrine and systemic adverse effects.
Because hypoxia causes conjunctiva – patients with sickle-cell anemia while wearing contact lenses after surgery (wound reduction).
Dosage
25 mg / ml
Indications
Iridocyclitis (for prevention of posterior synechiae and reduce exudation of the iris).
Mydriasis during ophthalmoscopy and other diagnostic procedures necessary to control the posterior segment of the eye condition in laser interventions in the fundus and vitreoretinal surgery.
Conducting provocative test in patients with narrow profile of anterior chamber angle and suspected closure glaucoma.
Differential diagnosis of superficial and deep injection of the eyeball.
Syndrome of “red eye” (to reduce redness and irritated mucous membrane of the eye).
Prevention asthenopia and accommodation spasm in patients with high visual load.
Treatment false myopia (spasm of accommodation) and prevention of the progression of myopia in patients true with high visual load.
Interaction with other drugs
Mydriatic phenylephrine effect is enhanced when used in combination with topical application of atropine.
Due to increased pressor action may develop tachycardia.
Use of 2.5% or 10% Irifrina® solution with monoamine oxidase inhibitors, as well as within 21 days after discontinuation of patients these drugs should be administered with caution, because in this case there is an uncontrolled rise in blood pressure.
Pressor effect of adrenergic agents may also be potentiated when combined with a tricyclic antidepressant, propranolol, reserpine, guanethidine, methyldopa and m-holinoblokatorami.
Using Irifrina® 10% solution in combination with systemic beta-blockers may cause severe hypertension.
Irifrin® may potentiate the inhibition of cardiovascular activity during inhalation anesthesia.
Application together with sympathomimetics may increase cardiovascular effects of phenylephrine.
Overdose
Overdose symptoms are anxiety, nervousness, dizziness, sweating, vomiting, heart palpitations, weak or shallow breathing.
When systemic action occurs phenylephrine arrest undesirable phenomena can be achieved by use of alpha-adrenoceptor blocking agents, for example, from 5 to 10 mg of phentolamine intravenously.
If necessary, the injection can be repeated.
pharmachologic effect
Pharmacological group:
Alpha -adrenomimetik.
Pharmacodynamics:
Phenylephrine – sympathomimetic. It has expressed the alpha-adrenergic activity.
The local application in ophthalmology causes dilation of the pupil, enhances the outflow of intraocular fluid and constricts blood vessels of the conjunctiva.
Phenylephrine has a strong stimulating effect on the postsynaptic alpha-adrenergic receptors, has very little effect on the beta-adrenergic receptors of the heart.
The drug has vasoconstrictor action similar to the action of norepinephrine (noradrenaline), while it is practically no chronotropic and inotropic effect on the heart.
Pressor effect of phenylephrine is weaker than that of norepinephrine, but is longer.
Causes vasoconstriction after 30-90 seconds after instillation, duration of 2-6 hours.
After instillation of phenylephrine reduces the iris dilator muscle and smooth muscle of the arterioles of the conjunctiva, thereby causing mydriasis.
Mydriasis occurs within 10-60 minutes after a single instillation. Continues after instillation of a 2.5% solution and maintained for 2 hours. Mydriasis caused by phenylephrine, is not accompanied by cycloplegic.
Pharmacokinetics:
Phenylephrine easily penetrates into the ocular tissue, the peak plasma concentration occurs within 10-20 minutes after topical application.
Phenylephrine is excreted by the kidneys in unchanged form (
Pregnancy and breast-feeding
The animals in late pregnancy phenylephrine caused fetal growth retardation and stimulated early onset of labor.
Action Irifrina® BC in pregnant women are poorly understood, therefore, to use the drug in such patients should be only if the expected benefit to the mother outweighs the risk of possible side effects to the fetus.
In the case of the appointment of the drug during lactation, breast-feeding should be discontinued.
Conditions of supply of pharmacies
On prescription.
side effects
Local.
Conjunctivitis, keratitis, periorbital edema, eye pain, burning during instillation, lacrimation, blurred vision, irritation, discomfort, increased intraocular pressure, blocking the anterior chamber angle (angle at the narrowing), allergic reactions, reactive hyperemia.
Phenylephrine can cause reactive cramps the day after application.
Repeated instillation of the drug at this time may give less pronounced mydriasis than the day before.
This effect is often seen in elderly patients.
Due to the significant reduction of pupil dilator exposed to phenylephrine in 30-45 minutes after instillation in the anterior chamber humidity may be detected by the pigment particles from the pigment leaf of the iris.
The slurry moisture in the chamber must be differentiated manifestations anterior uveitis or to exposure of blood cells in the anterior chamber of moisture.
System.
Contact dermatitis.
Cardio-vascular system:
Palpitations, tachycardia, arrhythmia, increased blood pressure, ventricular fibrillation, reflex bradycardia, coronary artery occlusion, pulmonary embolism.
In rare cases, after local use of 10% solution of phenylephrine may develop serious violations of the cardiovascular system, including myocardial infarction, vascular collapse and intracranial hemorrhage.
Storage conditions
In the dark place at a temperature not higher than 25 ° C. Do not freeze.
Keep out of the reach of children.
Dosing and Administration
When conducting ophthalmoscopy apply single instillation of 2.5% Irifrina® solution. Typically, to create sufficient mydriasis administration of 1 drop of 2.5% Irifrina® in the conjunctival sac.
Maximum mydriasis achieved after 15-30 minutes and lasts for 1-3 hours.
If necessary, maintaining mydriasis for a long time after 1 Hour Possibility Irifrina® repeated instillation.
In adults and children older than 12 years with little expansion of the pupil, as well as in patients with a rigid iris (pronounced pigmentation) for diagnostic mydriasis is possible to use 10% Irifrina® at the same dose.
To remove the spasm of accommodation 2.5% Irifrina® solution for children from 6 years and adults appoint 1 drop in each eye at night daily for 4 weeks.
In the case of persistent spasm of accommodation is possible to use 10% Irifrina® solution in children from 12 years and adults 1 drop in each eye daily at bedtime for 2 weeks.
For diagnostic procedures single instillation of 2.5% solution Irifrina® applies:
– as provocative test in patients with narrow profile of anterior chamber angle and suspected closure glaucoma. If the difference between the values ​​of intraocular pressure before instillation and after Irifrina® mydriasis is 3 to 5 mm Hg. Art., The provocation test is considered positive;
– for differential diagnosis of injection-type eyeball if 5 minutes after instillation marked vasoconstriction of the eyeball, the injection is classified as a surface, while maintaining the redness of the eyes should be carefully examine the patient for the presence of iridocyclitis or scleritis, as it shows the expansion of a more deep-lying vessels .
When iridotsiklitah 2.5% or 10.0% Irifrina® solution is used to prevent the development and breaking the already formed posterior synechiae; to reduce exudation into the anterior chamber of the eye. For this purpose, one drop of medication is dug into the conjunctival sac of the patient’s eyes (eye) 2-3 times a day.
In glaucoma-tsikliticheskih crises vasoconstrictor phenylephrine effect contributes to lower intraocular pressure, which is most pronounced when applying 10% of the drug solution. For relief of glaucoma-tsikliticheskih crises 10% Irifrin® buried 2-3 times a day.
In the preparation of patients for surgical procedures for 30-60 minutes prior to surgery to achieve produced mydriasis single instillation of 10% Irifrina® solution. After opening the eyeball membranes repeated instillation of the drug is not allowed. 10% solution is applied for irrigation, impregnation of tampons during surgical intervention for subconjunctival administration.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Sentis

There are no reviews yet.

Add your review